MRGPRX2 Inhibitor Program
Type 2 Inflammatory Diseases
Pre-clinicalActive
Key Facts
About Enanta Pharmaceuticals
Enanta Pharmaceuticals is a publicly traded biotech focused on creating novel oral therapeutics through innovative chemistry, with a proven track record in virology. The company's past success includes collaborating with AbbVie to discover two protease inhibitors (glecaprevir and paritaprevir) that are part of marketed HCV regimens that have cured over one million patients. Its current strategy is to replicate this success in new areas, with a clinical-stage pipeline targeting RSV and earlier-stage immunology programs for type 2 inflammatory diseases. Enanta is led by a seasoned management team and is driven by a mission to transform patient lives with curative therapies.
View full company profileTherapeutic Areas
Other Type 2 Inflammatory Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| STAT6 Inhibitor Program | Enanta Pharmaceuticals | Pre-clinical |